SI2402008T1 - Formulacije, ki vsebujejo amiodaron in sulfoalkil eter ciklodekstrin - Google Patents
Formulacije, ki vsebujejo amiodaron in sulfoalkil eter ciklodekstrinInfo
- Publication number
- SI2402008T1 SI2402008T1 SI200332474A SI200332474A SI2402008T1 SI 2402008 T1 SI2402008 T1 SI 2402008T1 SI 200332474 A SI200332474 A SI 200332474A SI 200332474 A SI200332474 A SI 200332474A SI 2402008 T1 SI2402008 T1 SI 2402008T1
- Authority
- SI
- Slovenia
- Prior art keywords
- formulations containing
- sulfoalkyl ether
- ether cyclodextrin
- containing amiodarone
- amiodarone
- Prior art date
Links
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 title abstract 2
- 229960005260 amiodarone Drugs 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 title 2
- 229920000858 Cyclodextrin Polymers 0.000 title 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title 1
- 125000004964 sulfoalkyl group Chemical group 0.000 title 1
- 208000020446 Cardiac disease Diseases 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/139,620 US6869939B2 (en) | 2002-05-04 | 2002-05-04 | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| EP11182697.0A EP2402008B1 (en) | 2002-05-04 | 2003-04-29 | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2402008T1 true SI2402008T1 (sl) | 2016-05-31 |
Family
ID=29399340
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200332474A SI2402008T1 (sl) | 2002-05-04 | 2003-04-29 | Formulacije, ki vsebujejo amiodaron in sulfoalkil eter ciklodekstrin |
| SI200332113T SI1501496T1 (sl) | 2002-05-04 | 2003-04-29 | Formulacije, ki vsebujejo amiodaron in sulfoalkil eter ciklodekstrin |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200332113T SI1501496T1 (sl) | 2002-05-04 | 2003-04-29 | Formulacije, ki vsebujejo amiodaron in sulfoalkil eter ciklodekstrin |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6869939B2 (enExample) |
| EP (2) | EP1501496B1 (enExample) |
| JP (2) | JP4764004B2 (enExample) |
| KR (1) | KR100984197B1 (enExample) |
| AT (1) | ATE535239T1 (enExample) |
| AU (1) | AU2003234285B2 (enExample) |
| CA (1) | CA2483774C (enExample) |
| CY (1) | CY1112527T1 (enExample) |
| DK (2) | DK1501496T3 (enExample) |
| ES (2) | ES2378306T3 (enExample) |
| HU (1) | HUE027551T2 (enExample) |
| IL (2) | IL165022A0 (enExample) |
| MX (1) | MXPA04010925A (enExample) |
| PT (1) | PT1501496E (enExample) |
| SI (2) | SI2402008T1 (enExample) |
| WO (1) | WO2003092590A2 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ548236A (en) | 2004-01-30 | 2010-02-26 | Pfizer Prod Inc | Compositions comprising (2S.3S) (2-benzhydryl-1-aza-bicyclo[2.2.2]oct-3-yl)-(5-alkyl-2-methoxy-benzyl)-amine derivatives |
| EP2708225B1 (en) | 2004-04-23 | 2018-12-26 | CyDex Pharmaceuticals, Inc. | DPI Formulation Containing Sulfoalkyl Ether Cyclodextrin |
| US8092559B2 (en) | 2004-05-12 | 2012-01-10 | Luca Technologies, Inc. | Generation of hydrogen from hydrocarbon bearing materials |
| US7426960B2 (en) | 2005-05-03 | 2008-09-23 | Luca Technologies, Inc. | Biogenic fuel gas generation in geologic hydrocarbon deposits |
| US20100204178A1 (en) | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
| US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| US7416879B2 (en) | 2006-01-11 | 2008-08-26 | Luca Technologies, Inc. | Thermacetogenium phaeum consortium for the production of materials with enhanced hydrogen content |
| ZA200808114B (en) | 2006-03-28 | 2009-12-30 | Javelin Pharmaceuticals Inc | Formulations of low dose non-steroidal anti-inflammatory drugs and betacyclodextrin |
| US8580954B2 (en) * | 2006-03-28 | 2013-11-12 | Hospira, Inc. | Formulations of low dose diclofenac and beta-cyclodextrin |
| US7696132B2 (en) * | 2006-04-05 | 2010-04-13 | Luca Technologies, Inc. | Chemical amendments for the stimulation of biogenic gas generation in deposits of carbonaceous material |
| US7977282B2 (en) | 2006-04-05 | 2011-07-12 | Luca Technologies, Inc. | Chemical amendments for the stimulation of biogenic gas generation in deposits of carbonaceous material |
| PT2061458E (pt) * | 2006-09-15 | 2015-03-11 | Univ Minnesota | Composições de topiramato e métodos para a sua utilização |
| US20090239942A1 (en) * | 2006-09-15 | 2009-09-24 | Cloyd James C | Topiramate Compositions and Methods of Making and Using the Same |
| US20090270496A1 (en) * | 2007-05-03 | 2009-10-29 | Courchesne William E | Antifungal compounds |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| US8479813B2 (en) | 2009-12-16 | 2013-07-09 | Luca Technologies, Inc. | Biogenic fuel gas generation in geologic hydrocarbon deposits |
| EP2335686A1 (en) | 2009-12-21 | 2011-06-22 | LEK Pharmaceuticals d.d. | An aqueous intravenous nanosuspension with reduced adverse effects |
| NL2004260C2 (en) * | 2010-02-18 | 2011-08-22 | Univ Amsterdam | Disinfectant composition and its use in dental treatment. |
| CN103079559A (zh) * | 2010-06-11 | 2013-05-01 | 巴克斯特国际公司 | 包含胺碘酮及其盐的制剂及其制造和使用方法 |
| CN103781484A (zh) | 2011-07-20 | 2014-05-07 | 赫思公司 | 治疗疼痛的方法 |
| HRP20200567T1 (hr) * | 2011-11-29 | 2020-06-26 | Jurox Pty Ltd | Stabilni injektabilni farmaceutski pripravci koji sadrže 2-hidroksipropil-beta-ciklodekstrin i alfaksalon |
| AU2013215237B2 (en) * | 2012-01-30 | 2017-11-23 | Baxalta GmbH | Non-anticoagulant sulfated or sulfonated polysaccharides |
| ES2774901T3 (es) | 2012-02-15 | 2020-07-23 | Cydex Pharmaceuticals Inc | Proceso para la fabricación de derivados de ciclodextrina |
| RU2615385C2 (ru) | 2012-02-28 | 2017-04-04 | Сидекс Фармасьютикалс, Инк. | Композиции алкилированного циклодекстрина и способы их получения и применения |
| US9004162B2 (en) | 2012-03-23 | 2015-04-14 | Transworld Technologies Inc. | Methods of stimulating acetoclastic methanogenesis in subterranean deposits of carbonaceous material |
| JP2015534970A (ja) * | 2012-10-17 | 2015-12-07 | ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＳＡＰＩＯＴＥＣ ＧｍｂＨ | 多発性骨髄腫の治療のためのアントシアニジン複合体 |
| AU2013334921B2 (en) | 2012-10-22 | 2018-03-29 | Cydex Pharmaceuticals, Inc. | Alkylated cyclodextrin compositions and processes for preparing and using the same |
| KR102147084B1 (ko) * | 2012-11-15 | 2020-08-24 | 자피오텍 게엠베하 | 소염성 활성 물질 또는 면역 억제성 활성물질로서 델피니딘 복합제 |
| EP2773033B1 (en) | 2013-02-28 | 2018-12-05 | Dialog Semiconductor GmbH | Divide by 2 and 3 charge pump methods |
| GB201312737D0 (en) | 2013-07-17 | 2013-08-28 | Univ Greenwich | Cyclodextrin |
| US10851184B2 (en) | 2014-08-22 | 2020-12-01 | Cydex Pharmaceuticals, Inc. | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same |
| US10736891B2 (en) * | 2016-01-07 | 2020-08-11 | Roy MADIGAN | Composition and method for treating chagas disease |
| WO2017149552A1 (en) * | 2016-03-04 | 2017-09-08 | Sun Pharmaceutical Industries Ltd. | Parenteral dosage form of amiodarone |
| CN107753439A (zh) * | 2016-08-22 | 2018-03-06 | 黑龙江迪龙制药有限公司 | 一种注射用盐酸胺碘酮及其制备方法 |
| WO2018091668A1 (en) | 2016-11-18 | 2018-05-24 | Aicuris Anti-Infective Cures Gmbh | Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions |
| US12416024B2 (en) | 2018-03-29 | 2025-09-16 | Transworld Technologies Inc. | Biologically enhanced oil recovery methods |
| CN114126596A (zh) * | 2019-05-15 | 2022-03-01 | 贝克森生物医药公司 | 用于皮下注射的氯胺酮制剂 |
| WO2021026310A1 (en) | 2019-08-06 | 2021-02-11 | L.E.A.F. Holdings Group Llc | Processes of preparing polyglutamated antifolates and uses of their compositions |
| CA3198795A1 (en) | 2020-11-18 | 2022-05-27 | Jeffrey Becker | Complexing agent salt formulations of pharmaceutical compounds |
| CN115969833A (zh) * | 2023-01-03 | 2023-04-18 | 上海上药第一生化药业有限公司 | 胺碘酮药物组合物、注射液及其制备方法及含其的注射器 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991004026A1 (en) | 1989-09-14 | 1991-04-04 | Australian Commercial Research & Development Limited | Drug delivery compositions |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| EP0518930A4 (en) | 1990-03-02 | 1993-09-15 | Australian Commercial Research & Development Limited | Cyclodextrin compositions and methods for pharmaceutical and industrial applications |
| US5234949A (en) | 1992-04-01 | 1993-08-10 | Academic Pharmaceuticals, Inc. | Parenteral solutions containing amiodarone in acetate buffer solution |
| FR2735978B1 (fr) | 1995-06-30 | 1997-09-19 | Sanofi Sa | Composition pharmaceutique d'amiodarone pour administration parenterale |
| UA57734C2 (uk) * | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
| US5916883A (en) | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
| US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| US5874418A (en) * | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| UA67825C2 (uk) | 1999-01-21 | 2004-07-15 | Брістол-Майерс Сквібб Ко. | КОМПЛЕКС ІНГІБІТОРА RAS-ФАРНЕЗИЛТРАНСФЕРАЗИ ТА ПРОСТОГО СУЛЬФОБУТИЛОВОГО ЕФІРУ 7-<font face="Symbol">b</font>-ЦИКЛОДЕКСТРИНУ АБО 2-ГІДРОКСИПРОПІЛ-<font face="Symbol">b</font>-ЦИКЛОДЕКСТРИНУ, КОМПОЗИЦІЯ ІНГІБІТОРА RAS-ФАРНЕЗИЛТРАНСФЕРАЗИ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| GB9921958D0 (en) * | 1999-09-16 | 1999-11-17 | Pharmacia & Upjohn Spa | Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins |
| US6479541B1 (en) * | 2000-03-30 | 2002-11-12 | Baxter International | Amiodarone-containing parenteral administration |
-
2002
- 2002-05-04 US US10/139,620 patent/US6869939B2/en not_active Expired - Lifetime
-
2003
- 2003-04-29 DK DK03728598.8T patent/DK1501496T3/da active
- 2003-04-29 EP EP03728598A patent/EP1501496B1/en not_active Expired - Lifetime
- 2003-04-29 IL IL16502203A patent/IL165022A0/xx unknown
- 2003-04-29 ES ES03728598T patent/ES2378306T3/es not_active Expired - Lifetime
- 2003-04-29 EP EP11182697.0A patent/EP2402008B1/en not_active Expired - Lifetime
- 2003-04-29 MX MXPA04010925A patent/MXPA04010925A/es active IP Right Grant
- 2003-04-29 JP JP2004500775A patent/JP4764004B2/ja not_active Expired - Lifetime
- 2003-04-29 SI SI200332474A patent/SI2402008T1/sl unknown
- 2003-04-29 PT PT03728598T patent/PT1501496E/pt unknown
- 2003-04-29 KR KR1020047017639A patent/KR100984197B1/ko not_active Expired - Lifetime
- 2003-04-29 WO PCT/US2003/013250 patent/WO2003092590A2/en not_active Ceased
- 2003-04-29 CA CA2483774A patent/CA2483774C/en not_active Expired - Lifetime
- 2003-04-29 AT AT03728598T patent/ATE535239T1/de active
- 2003-04-29 HU HUE11182697A patent/HUE027551T2/en unknown
- 2003-04-29 AU AU2003234285A patent/AU2003234285B2/en not_active Expired
- 2003-04-29 DK DK11182697.0T patent/DK2402008T3/en active
- 2003-04-29 ES ES11182697.0T patent/ES2567716T3/es not_active Expired - Lifetime
- 2003-04-29 SI SI200332113T patent/SI1501496T1/sl unknown
-
2004
- 2004-11-04 IL IL165022A patent/IL165022A/en active IP Right Grant
-
2011
- 2011-03-07 JP JP2011048873A patent/JP5656692B2/ja not_active Expired - Lifetime
-
2012
- 2012-02-23 CY CY20121100190T patent/CY1112527T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2483774C (en) | 2011-07-19 |
| JP5656692B2 (ja) | 2015-01-21 |
| KR100984197B1 (ko) | 2010-09-28 |
| EP2402008B1 (en) | 2016-01-27 |
| DK2402008T3 (en) | 2016-05-02 |
| EP1501496A2 (en) | 2005-02-02 |
| EP2402008A1 (en) | 2012-01-04 |
| PT1501496E (pt) | 2012-02-20 |
| JP2005530744A (ja) | 2005-10-13 |
| ATE535239T1 (de) | 2011-12-15 |
| US6869939B2 (en) | 2005-03-22 |
| US20030216353A1 (en) | 2003-11-20 |
| WO2003092590A3 (en) | 2004-01-22 |
| HUE027551T2 (en) | 2016-10-28 |
| AU2003234285B2 (en) | 2007-01-04 |
| DK1501496T3 (da) | 2012-03-19 |
| EP1501496B1 (en) | 2011-11-30 |
| JP2011116776A (ja) | 2011-06-16 |
| WO2003092590A2 (en) | 2003-11-13 |
| ES2378306T3 (es) | 2012-04-11 |
| IL165022A0 (en) | 2005-12-18 |
| EP1501496A4 (en) | 2006-05-31 |
| IL165022A (en) | 2011-08-31 |
| CY1112527T1 (el) | 2015-12-09 |
| MXPA04010925A (es) | 2005-02-14 |
| KR20040106452A (ko) | 2004-12-17 |
| ES2567716T3 (es) | 2016-04-26 |
| CA2483774A1 (en) | 2003-11-13 |
| SI1501496T1 (sl) | 2012-04-30 |
| AU2003234285A1 (en) | 2003-11-17 |
| JP4764004B2 (ja) | 2011-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL165022A0 (en) | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin | |
| IL154888A (en) | Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid | |
| AU2002325856A1 (en) | Agent containing fat (oil), which contains onion extract, the production and use thereof for caring, preventing or treating damaged skin tissue, especially scarred tissue | |
| WO2003028802A3 (en) | Devices for treating atrial fibrilation | |
| EP1465492A4 (en) | LIQUID COMPOSITION FOR PROMOTING PLANT GROWTH CONTAINING NANOPARTICULAR TITANIUM DIOXIDE | |
| PL1643833T3 (pl) | Formulacje agrochemiczne | |
| IL164533A0 (en) | Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds | |
| MXPA05013232A (es) | Composicion en forma de pulverizador que comprende un activo farmaceutico, al menos una silicona volatil y una fase aceitosa no volatil. | |
| WO2001078702A3 (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
| IL216579A0 (en) | Aminocyclohexyl ether derivatives and pharmaceutical compositions containing the same | |
| WO2001015715A3 (en) | Composition for maintenance of bone or dental health or treatment of bone or dental disorders | |
| CY1107942T1 (el) | Ψεκασιμη συνθεση για τη χορηγηση παραγωγων της βιταμινης d | |
| WO2000066528A3 (en) | Quinones for treatment of diseases | |
| TW200510367A (en) | Novel lapachone compounds, their preparation, and the use thereof | |
| AU9543601A (en) | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | |
| WO2002039997A3 (en) | Ace-2 modulating compounds and use thereof | |
| PL350917A1 (en) | C16 unsaturated fp-selective prostaglandins analogs | |
| WO2004098522A3 (en) | Gemini vitamin d3 compounds and methods of use thereof | |
| TW200513264A (en) | Remedy and a therapeutic method for periodontal diseases and pulpal diseases | |
| IL150527A0 (en) | Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives | |
| PL368040A1 (en) | Substituted 4-aminocyclohexanol derivatives | |
| EP1574507A3 (en) | Furo- and pyrano-naphthoquinones and their use in the treatment of cancer | |
| WO2004052331A3 (fr) | Utilisation d'un extrait de miellat de coton comme ingredient acitif | |
| NO20060655L (no) | 2-alkyliden-19-Nor-vitamin D derivater for behandling av osteofeni eller osteoporose hos hannkjonn | |
| AU2003216738A1 (en) | Method for treatment of a region of the skin of a human subject, in particular cosmetic treatment by the trans-epidermal route using projection of a liquid under pressure |